RxDoctor Payments Data

Osemwota Omoigui, MD

Pain Medicine · Hawthorne, CANPI 1497825467

Payments from drug & device makers

$754in general payments, 2019–2025

Across 14 payments — averaging $53.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$380
  • Coloplast$127
  • SPR Therapeutics, Inc$96
  • AbbVie$37
  • Amgen$32
  • Kyowa Kirin, Inc.$29
  • plus $53 from 4 others

What the payments were for

  • Travel & lodging$22830%
  • Food & beverage$52670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$754 in reported general payments places this provider in the 35th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$175,203
Medicare patients
44
Services billed
7,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$58,822
MounjaroTirzepatide22$22,352
UbrelvyUbrogepant15$19,914
Nurtec OdtRimegepant Sulfate14$15,438
MovantikNaloxegol Oxalate23$9,417
Oxcarbazepine163$3,613
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen285$3,324
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$2,181
Pregabalin99$1,243
Albuterol Sulfate HfaAlbuterol Sulfate22$959
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen73$951
Gabapentin42$804
Raloxifene Hcl30$780
Famotidine152$622
Tizanidine Hcl170$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$18$22,35222 claims
AbbVieUbrelvy$37$19,91415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 840 pain medicine providers in California.

Other pain medicine in Hawthorne

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →